Page 110 - 81_04

33. Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D,
Jans DA. Ivermectin is a specific inhibitor of importin
a/ß-mediated nuclear import able to inhibit replication 46. OMS, 2014. Prevention, control and elimination of
of HIV-1 and dengue virus. Biochem J. 2012; 443 (Pt
3): 851–856.
34. Sharmeen S, Skrtic M, Sukhai MA, Hurren R, Gronda
M, Wang X, Fonseca SB, Sun H, Wood TE, Ward R,
Minden MD, Batey RA, Datti A, Wrana J, Kelley SO,
Schimmer AD. The anti-parasitic agent ivermectin
induces chloride dependent membrane
hyperpolarization and cell death in leukemia cells.
Blood. 2010; 116: 3593-3603.
35. Costa JL, Diazgranados JA. 1993.Treatment of human
diseases involving dysregulation or dysfunction of the
nervous system. US 5189026 A;
http://www.google.com/patents/ US5189026
36. Egerton JR, Brokken ES, Suhayda S, Eary CH,
Wooden JV, Kilgore RL. The antiparasitic activity of
ivermectin in horses. Vet Parasitol. 1981; 8: 83-88.
37. WHO 2010. First WHO Report on Neglected Diseases:
http://www.who.int/neglected_diseases/2010report/en/
38. Ibid 13. Capítulo 21. Greene BM, Brown KR, Taylor
R. Use of Ivermectin in Humans.
39. Elgart GW, Meinking TL. Ivermectin. Dermatol Clin.
2003; 21 (2): 277-82.
40. El orgullo de regalar: la historia de la lucha contra la
“ceguera de los ríos”.
http://www.compromisoempresarial.com/entradas/200
8/01/el-orgullo-de-regalar-la-historia-de-la-lucha-
contra-la-ceguera-del-rio/.
41. Benin, Burkina Faso, Burundi, Camerún, Chad, Congo,
Costa de Marfil, República Democrática del Congo,
Etiopía, Guinea Ecuatorial, Ghana, Guinea, Guinea
Bissau, Liberia, Malawi, Mali, Nigeria, Senegal,
Sierra Leone, Sudan, Sudán del Sur, Togo, Uganda y
Tanzania (ibid 38).
42. Halliday A, Gentil K, Hoerauf A, Pearlman E, Taylor
MJ, Tamarozzi F. Onchocerciasis: the Role of
Wolbachia Bacterial Endosymbionts in Parasite
Biology, Disease Pathogenesis, and Treatment. Clin.
Microbiol Rev. 2011; 24(3): 459-468.
43. OMS/African Program for Onchocerciasis Control:
Progress Report 2011 y OMS African Program for
Onchocerciasis Control: Meeting of National Task
Forces. Wkly. Epidemiol Rec. 2011; 48-86: 541-549.
44. OMS (2012) Integrated Preventive Chemotherapy for
Neglected Tropical Diseases: Estimation of the
Number of Interventions Required and Delivered,
2009–2010, WHO Mectizan Donation Program (2012)
Annual Highlights 2011: Celebrating 25 years of the
Mectizan Donation Program in 2012:
http://www.mectizan.org/sites/default/files/Annual%20Hig
hlights%202011%20English.pdf
45. Mectizan Donation Program:
http://www.mectizan.org/news/international-coalition-
urges-final-push-to-eliminate-river-blindness-from-
the-americas.
378
Antonio R. Martínez Fernández
onchocerciasis.
http://www.who.int/onchocerciasis/control/en/
47. Lustigman S, McCarter J. Ivermectin resistance in
Onchocerca volvulus: Toward a genetic basis. PloS
Ngl Trop Dis. 2007; 1 (1): e76.
48. Boussinesq M, Kamgno J, Pion SD, Gardon J. What
are the mechanisms associated with post-ivermectin
serious adverse events? Trends in Parasitology. 2006;
22 (6): 244-246.
49. Campbell, W.C. Ed. Trichinella and Trichinosis. New
York: Springer-Verlag, 1983.
50. Brown D, Matzuk AR, Ilves IR, Peterson LH, Harris
SA, Sarett LH, Egerton JR, Yakstis JJ, Campbell WC,
Cuckler J AC. Antiparasitic Drugs. Iv. 2-(4'-
Thiazolyl)-Benzimidazole, A New Anthelmintich. Am
Chem Soc. 1961; 83 (7): 1764-5.
51. Martínez Fernández, A.R. Investigaciones sobre la
eficacia de la methiridina y del thiabendazol frente a
Trichinella spiralis (Owen 1835) Railliet, 1895. Tesis
doctoral. Universidad de Oviedo. An Fac Vet León.
1966; 11: 127-216.
52. Campbell, W.C. Poem, Paint and Pathogen.
Prospectives in Biology and Medicine. 1989; 32: 3.
53. Satoshi Omura/Curriculum vitae/2014:
http://www.satoshi-
omura.info/biography/omura_cv.pdf.
54. Omura S. Microbial metabolites: 45 years of
wandering, wondering and discovering. Tetrahedron.
2011; 67: 6420-e6459.
55. Kita K, Shiomi K, Omura S. Advances in drug
discovery and biochemical studies. Trends in
Parasitology. 2007; 23 (5): 223-9.
56.OMS,http://www.who.int/malaria/publications/world_
malaria_ report_2014/en/
57. Watt G, Loesuttivibool L, Shanks GD, Boudreau EF,
Brown AE, Pavanand K, Webster HK, Wechgritaya S.
Quinine with tetracycline for the treatment of drug-
resistant falciparum malaria in Thailand. Am J Trop
Med Hyg. 1992; 47 (1): 108-11.
58. Schlitzer M. Malaria chemotherapeutics Part I. History
of antimalarial drugs development, currently used
therapeutics, and drug in clinical development. Chem
Med Chem. 2007; 2: 944-86.
59. Raviña E. Medicamentos. Un viaje a lo largo de la
evolución histórica del descubrimiento de los
fármacos. Santiago de Compostela: Universidad de
Santiago de Compostela, 2008; vol. I, pp. 255-219
60. Meshnick SR, Dobson MJ. The history of antimalarial
drugs. In: Rosenthal PJ. Ed. Antimalarial
Chemotherapy: Mechanisms of Action, Resistance,
and New Directions in Drug Discovery. Totowa:
Humana Press Inc.; pp. 1-25.
61. Ognibene AJ, Conte, NF. History of the Office of
Medical History. Chapte 14. Malaria Chemotherapy.
US Army Medical Departmen: 1960-65.
@Real Academia Nacional de Farmacia. Spain